Reach Us +44-3308187254


Interaction Of Drugs At Organic Cation Transporters In The Plasma Membrane: Mechanistics, Risks And Benefits | 13309
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Interaction of drugs at organic cation transporters in the plasma membrane: Mechanistics, risks and benefits

International Summit on Clinical Pharmacy & Dispensing

Hermann Koepsell

Accepted Abstracts: Clinic Pharmacol Biopharmaceut

DOI: 10.4172/2167-065X.S1.004

In human eight polyspecific ATP independent organic cation transporters have been identified. Transporters OCT1, OCT2, OCT3, OCTN1, OCTN2 and CT2 belong to the SLC22 family whereas transporters MATE1, MATE2-K belong to the SLC47 family. OCT1-3 are cation facilitators that predominantly mediate cation uptake at physiological membrane potential. OCTN1, MATE1 and MATE2-K are proton-cation antiporters that mediate cation efflux, however, they may also transport cations into cells. Similarly OCTN2 and CT2 can function as uptake and efflux systems. All cation transporters have overlapping cation selectivities. They are critically involved in small intestinal absorption and hepatic and/or renal excretion of hydrophilic cationic drugs such as metformin and cisplatin. In general several polyspecific cation transportes are located within a given plasma membrane. In case of common substrates loss of function of one transporter may be compensated. Blockage hOCT2 in the basolateral membrane of renal proximal tubules or of MATE2-K in the luminal membrane may slow down cisplatin excretion, however, the effect on cisplatin-induced kidney damage may be opposite. Knowledge about structure function relationship of cation binding to OCTs is used as paradigm for ligand binding to all ATP independent polyspecific cation transporters. The OCTs contain a binding cleft with overlapping ligand binding domains. For a given ligand the cleft may contain high and low affinity binding sites which may be inhibitory. Since ligand binding may induce short-term allosteric effects within the cleft a given ligand often blocks translocation of different cations with different affinities. The clinical consequences of these findings will be discussed.
Hermann Koepsell studied medicine and finshed MD in 1972. From 1978-1992 he had a research group at the Max-Planck-Institut of Biophysics in Frankfurt, Germany. From 1993-2011 H. Koepsell was chairman of the Insititute of Anatomy and Cell Biology at the University of W?rzburg (Germany). Since 2012 H. Koepsell continues his scientific investigations at the Julius-von-Sachs Institute in W?rzburg. H. Koepsell identified the first transporter of the SLC22 family. His scientific contributions include the elucidation of structure and function of organic cation transporters and the regulation of glucose transporters. He is member of the German National Academy of Sciences Leopoldina.